Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

Merck (MRK) stock returned 78.7% in the twelve months to October 21, 2026, against 16.5% for the S&P 500. Over that year, ...

Merck KGaA agreed to acquire Silence Therapeutics Plc for about $1.1 billion in a cash transaction as the German science ...

The $20-per-ADS all-cash acquisition agreement follows Phase 2 progress for Divesiran and is expected to close in the first ...

Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...

Merck stock looks fairly valued as Keytruda risks, slower EPS growth, and debt weigh on upside. Click here to read an ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over the ...

His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia ...

Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with ...

Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...

US pharma major Merck & Co (NYSE: MRK) and US biotech Moderna (Nasdaq: MRNA) have reported detailed Phase III results showing ...

Germany’s Merck KGaA has agreed to acquire British biotechnology company Silence Therapeutics for approximately $1.3 billion ...